In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors

Journal of Infectious Diseases

Volumn 180, Issue 2, 1999, Pages 448-453

  Cassone, Antonio ^a   De Bernardis, Flavia ^a   Torosantucci, Antonella ^a   Tacconelli, Evelina ^b   Tumbarello, Mario ^b   Cauda, Roberto ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; ASPARTIC PROTEINASE INHIBITOR; DIMETHYL SULFOXIDE; FLUCONAZOLE; INDINAVIR; PEPSTATIN; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; VAGINA CANDIDIASIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIFUNGAL AGENTS; ASPARTIC ENDOPEPTIDASES; CANDIDA ALBICANS; CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; PEPSTATINS; PROTEASE INHIBITORS; RATS; RITONAVIR;

EID: 0033509027     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314871     Document Type: Article

References (32)

1. 1. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998; 351:228-30.
2. 2. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-4.
3. 3. Centers for Disease Control and Prevention. Update: trends in AIDS incidence. MMWR Morb Mortal Wkly Rep 1997; 46:165-73.
4. 4. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256-61.
5. 5. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996; 334:1674-5.
6. 6. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
7. 7. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
8. 8. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of HIV-infected subjects treated with HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173:321-9.
9. 9. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:318-26.
10. 10. Angel JB, Kuman A, Paralo K, et al. Improvement in cell-mediated immune functions during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998; 177:898-904.
11. 11. Hube B. Candida albicans secreted aspartyl proteinases. Curr Top Med Mycol 1996; 7:55-69.
12. 12. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 1987; 156:777-83.
13. 13. De Bernardis F, Cassone A, Sturtevant J, Calderone R. Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun 1995; 63:1887-92.
14. 14. De Bernardis F, Agatensi T., Ross IK, et al. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J Infect Dis 1990; 161:1276-83.
15. 15. De Bernardis F, Arancia S, Morelli L, et al. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179:201-8.
16. 16. De Bernardis K, Chiani P, Ciccozzi M, et al. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun 1996; 64:466-71.
17. 17. Ollert MW, Wende C, Gorlich M, et al. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus positive patients. J Clin Microbiol 1995; 33:2543-9.
18. 18. de Bernardis F, Mondello F, Scaravelli G, et al. High aspartyl proteinase production and vaginitis in human immunodeficiency virus infected women. J Clin Microbiol 1999; 37:1376-80.
19. 19. Carr A. Cooper DA. HIV protease inhibitors. AIDS 1996; 10 (Suppl A): 151-7.
20. 20. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990; 20:358-61.
21. 21. Flexner C. HIV protease inhibitors. N Engl J Med 1998; 338:1281-92.
22. 22. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997; 65:3399-405.
23. 23. Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr Hum Retrovirol 1999 21:20-5.
24. 24. Angiolella L, De Bernardis F, Bromuro C, Mondello F, Ceddia T, Cassone A. The effects of antimycotics on secretory acid proteinase of Candida albicans. J Chemother 1990; 2:55-61.
25. 25. Deeks SG, Smith M, Holodniy I, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277:145-55.
26. 26. Beansejour A, Grenier D, Goulet JP, Deslauriers N. Proteolytic activation of the interleukin 1β precursor by Candida albicans. Infect Immun 1998; 66: 676-81.
27. 27. Gruber A, Lukasser-Volg E, Borg-von Zepzlin M, Dierich MP, Wurznr R. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis 1998; 177:1057-63.
28. 28. Fidel PL, Sobel JD, Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 5:335-48.
29. 29. Sobel J, Hasagawan A, De Bernardis F, et al. Selected animal models: vaginal candidosis, Pneumocystis pneumonia, dermatophytosis and trichosporonosis. Med Mycol 1998; 36:129-36.
30. 30. Danner SA, Carr A, Leonard J. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333:1528-33.
31. 31. Hughens PWH, Burger DM, Hoetelmans RMW, et al. Saliva as a possible specimen for monitoring compliance and plasma levels in patients treated with indinavir [abstract 32330]. In: Program and abstracts: 12th World AIDS Conference, (Geneva). Stockholm: International AIDS Society, 1998.
32. - T-helper cell responses in mice with low-level Candida albicans infection. Infect Immun 1996; 64: 4907-14.